430 related articles for article (PubMed ID: 22319204)
21.
Nanjo S; Arai S; Wang W; Takeuchi S; Yamada T; Hata A; Katakami N; Okada Y; Yano S
Mol Cancer Ther; 2017 Mar; 16(3):506-515. PubMed ID: 28138027
[TBL] [Abstract][Full Text] [Related]
22. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ
Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111
[TBL] [Abstract][Full Text] [Related]
24. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
25. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
26. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI
Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670
[TBL] [Abstract][Full Text] [Related]
27. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
28. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
[TBL] [Abstract][Full Text] [Related]
29. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
30. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Taguchi F; Koh Y; Koizumi F; Tamura T; Saijo N; Nishio K
Cancer Sci; 2004 Dec; 95(12):984-9. PubMed ID: 15596048
[TBL] [Abstract][Full Text] [Related]
31. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
32. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
33. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
[TBL] [Abstract][Full Text] [Related]
34. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
[TBL] [Abstract][Full Text] [Related]
35. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
36. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
Rai K; Takigawa N; Ito S; Kashihara H; Ichihara E; Yasuda T; Shimizu K; Tanimoto M; Kiura K
Mol Cancer Ther; 2011 Sep; 10(9):1720-7. PubMed ID: 21712475
[TBL] [Abstract][Full Text] [Related]
37. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
38. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Xu J; Zeng LF; Shen W; Turchi JJ; Zhang ZY
Biochem Biophys Res Commun; 2013 Oct; 439(4):586-90. PubMed ID: 24041688
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]